Who are Cetirizine Dry Syrup's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bepreve, bepotastine besilate ophthalmic solution, Levocetirizine (drug), olopatadine 0.2% ophthalmic solution, Xarlin (Levocetirizine), Cetirizine drops.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cetirizine-dry-syrup.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cetirizine Dry Syrup — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cetirizine Dry Syrup (Cetirizine Dry Syrup) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist (second-generation antihistamine). Area: Allergy/Immunology.

phase 3 H1-receptor antagonist (second-generation antihistamine) H1-receptor Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Cetirizine Dry Syrup (Cetirizine Dry Syrup) — GlaxoSmithKline. Cetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cetirizine Dry Syrup TARGET	Cetirizine Dry Syrup	GlaxoSmithKline	phase 3	H1-receptor antagonist (second-generation antihistamine)	H1-receptor
Bepreve	BEPOTASTINE	Bausch Health	marketed	Histamine-1 Receptor Antagonist	H1-receptor, mast cells	2009-01-01
bepotastine besilate ophthalmic solution	bepotastine besilate ophthalmic solution	Bausch & Lomb Incorporated	marketed		H1-receptor, mast cells
Levocetirizine (drug)	Levocetirizine (drug)	UCB Pharma	marketed	H1-receptor antagonist (second-generation antihistamine)	H1-receptor
olopatadine 0.2% ophthalmic solution	olopatadine 0.2% ophthalmic solution	Allergan	marketed	H1-receptor antagonist	H1-receptor
Xarlin (Levocetirizine)	Xarlin (Levocetirizine)	HK inno.N Corporation	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 receptor
Cetirizine drops	Cetirizine drops	UCB Pharma	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist (second-generation antihistamine) class)

UCB Pharma · 5 drugs in this class
Organon and Co · 3 drugs in this class
Brian J Lipworth · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Goldman, Butterwick, Fitzpatrick and Groff · 1 drug in this class
HK inno.N Corporation · 1 drug in this class
AAADRS Clinical Research Center · 1 drug in this class
University Hospital, Grenoble · 1 drug in this class
Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cetirizine Dry Syrup — Competitive Intelligence Brief. https://druglandscape.com/ci/cetirizine-dry-syrup. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab